BC
CYTK icon

Bayforest Capital’s Cytokinetics CYTK Stock Holding History

Bayforest Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Buy
2,143
+1,050
+96% +$75.4K 0.17% 202
2026
Q1 		$72K Buy
+1,093
New +$69.5K 0.08% 462
2025
Q4 		– Sell
-11,747
Closed -$646K – 827
2025
Q3 		$646K Buy
+11,747
New +$484K 0.31% 76
2025
Q2 		– Sell
-7,372
Closed -$296K – 781
2025
Q1 		$296K Buy
7,372
+5,683
+336% +$261K 0.13% 302
2024
Q4 		$79.5K Buy
+1,689
New +$87.7K 0.1% 367

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's CYTK Position: Q2 2026 in Review

Bayforest Capital increased its Cytokinetics (CYTK) stake by 96% in Q2 2026, buying an estimated $75.4K and bringing the position to 2,143 shares worth $183K. The position accounts for 0.17% of the portfolio, ranked #202.

Bayforest Capital first reported a position in CYTK in Q4 2024 and has held it in 5 quarters since. The position peaked at $646K in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Bayforest Capital held 2,143 shares of Cytokinetics worth $183K as of Q2 2026.
  • Bayforest Capital bought 1,050 Cytokinetics shares in Q2 2026, an estimated $75.4K.
  • Cytokinetics made up 0.17% of Bayforest Capital's portfolio in Q2 2026, its #202 holding.
  • Bayforest Capital first reported a position in Cytokinetics in Q4 2024 and has held it in 5 quarters since.
  • Bayforest Capital's Cytokinetics position peaked at $646K in Q3 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.